Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2020 | Story Leonie Bolleurs | Photo Supplied
Liezel Rudolph believes opportunities do not fall into your lap, but you cross them when you do what you love, and you do it well.

On more than one occasion, Liezel Rudolph set foot on the SA Agulhas II, travelling the oceans to Marion Island in her quest to research climate change. She focuses her research on reconstructing the past climate of Marion Island. 

As Lecturer in Process Geomorphology in the Department of Geography Rudolph is involved in research on glacial and peri-glacial landforms, trying to understand the links between climate and the processes that shape these landforms.

An interview with her reveals more about this scientist, adventurer, and teacher who sees pursuing one’s research interests and teaching others about it as a dream come true.

 

“Part of being a woman is to know when to be strong and to speak up, and when to be humble and listen.” – Liezel Rudolph

Is there a woman who inspires you, who you would like to celebrate this Women’s Month?

“I would like to celebrate my mother who does everything to the full. She celebrates the little things; she dreams big and she does not fear the future. She values discipline, but nurtures growth and has always encouraged (me) to be the best version of me and not to compare myself to others.”

What are some of the challenges you have faced in your life that have made you a better woman?

“I don’t like being criticised and I don’t like failing. It has taken me several years to learn that not all criticism is negative and that not all failures are final. And that is OK. I have learned to be easier on myself, and on others when I (or they) don’t meet certain expectations.”

What advice would you give to the 15-year-old you?

“When I was 15 years old, I had no idea what life would be after school – and it scared me. I now know that by following my passion and doing what I am good at, I am doing myself and the world a favour. There is no point in making loads of money if you hate going to work every day. Opportunities do not fall into your lap, but you cross them when you do what you love, and you do it well.”

What would you say makes you a champion woman [of the UFS]?

“I would not say that I am a champion woman, yet. But I would like to think that I am a woman who does her job well, and who does ‘woman’ well, too. This means bringing what I have to the table, and not comparing, criticising, or competing with anyone about what else is on the table. I still have to grow a lot in this regard.”

 

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept